Trial Profile
A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Once or Twice Daily for 12 Weeks in Subjects With Moderate to Severe Inflammatory Facial Acne Vulgaris
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs VB 1953 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Vyome Therapeutics
- 16 Jun 2020 Primary endpoint has been met. (Inflammatory lesion counts), according to a Vyome Therapeutics media release.
- 16 Jun 2020 Results published in the Vyome Therapeutics media release
- 30 Sep 2019 Status changed from recruiting to active, no longer recruiting.